| Today’s Big NewsFeb 12, 2024 |
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now! 
|
|
| By Annalee Armstrong,Gabrielle Masson More biotech companies filed for bankruptcy in 2023 than any year since 2010, underscoring a brutal year defined by layoffs, company closures and pipeline reprioritizations. |
|
|
|
By Angus Liu Takeda's Eohilia has surprisingly won over the FDA even after the company had at one point abandoned the program following an FDA rejection. But the first FDA-approved oral eosinophilic esophagitis therapy comes with a limitation. |
By Andrea Park Amid rumors that Apple is in the process of adding a sleep apnea detection feature to its namesake wearables, Samsung has beat it to the punch. |
By Nick Paul Taylor Pfizer has touched down at the Super Bowl. The Big Pharma ran its “Here’s to Science” ad at the event, framing its work to “outdo cancer” as part of a history of breakthroughs dating back to Hippocrates. |
|
Thursday, March 21, 2024 | 11am ET / 8am PT Join us for a discussion on the evolution of HCP engagement through the lens of Customer Science – the integration of data science, behavioral science, and AI. In this webinar, we explore how Customer Science brings substantial benefits to commercial leaders, providing a deeper understanding of HCPs and patients for more effective engagement. Register now. 
|
|
By Annalee Armstrong Gilead is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis med seladelpar. |
By Andrea Park About a week after the FDA convened another meeting to discuss strategies for reducing racial biases in widely available pulse oximetry technology, Masimo has released new study data suggesting that such measures won’t be needed for its own blood oxygen sensors. |
By James Waldron CSL’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. |
By Eric Sagonowsky After a series of regulatory setbacks in Europe, PTC Therapeutics will soon find itself under a generic attack in the U.S. |
By James Waldron What do you get when you merge six dermatology disease-focused biotechs into one? Medicxi plans to find out. |
By Conor Hale “This is the most significant update of Versius since it launched back in 2019,” CEO Supratim Bose said in the company’s announcement. |
By Zoey Becker Gritstone opted to kick off the phase 2b study in the fall instead of this quarter to "allow use of fully GMP-grade raw materials," according to the company. The move is meant to hopefully increase the trial's regulatory value. |
By Conor Hale Researchers at Virginia Commonwealth University have shown that a urine-based test could have the potential to become a simplified screening method. |
By Nick Paul Taylor AstraZeneca is working with the National Hockey League (NHL) to encourage people to “Get Body Checked Against Cancer.” The campaign is designed to encourage sports fans to ask their doctors about available cancer screenings and address low awareness of asymptomatic detection recommendations. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
